UNC, Vanderbilt discover new live vaccine approach for SARS and novel coronaviruses

November 12, 2012 — Scientists may have found a way to cripple the ability of the deadly SARS-coronavirus to cause disease in animals. The key lies in actually using the virus’ rapid mutation abilities against itself.

Ralph Baric, PhD. Photo by Dan Sears.

The findings by researchers at The University of North Carolina in Chapel Hill and Vanderbilt University were published in the Nov. 12 issue of Nature Medicine.

The study demonstrates that a SARS (severe acute respiratory syndrome) coronavirus, altered to lack the ability to “proofread” (correct mistakes in replication), begins to mutate much more rapidly and becomes unable to cause disease in mouse models. In effect, the alteration results in a profoundly weakened or attenuated SARS virus.  The finding may allow scientists to explore a new option for creating safer live vaccines.

Rapid mutation long has been considered a key to viral adaptation to environmental change. However, in the case of the coronavirus responsible for SARS, the researchers found that accelerating the rate of mutations disables the virus’s ability to cause disease in animals.

“We originally thought that the virus might find a way to fix the mutations we engineered or work around them as viruses often do,” said Rachel Graham, PhD, postdoctoral research associate in epidemiology at the Gillings School of Global Public Health at UNC, who led the research. “That didn’t happen, and in this case, the attenuated viruses replicated well enough and long enough to generate a protective immune response, even in immunocompromised animals, so it works wonderfully as a vaccine in an animal model.”

This work may offer reassurance at a critical time. Public attention was recently heightened regarding a novel human coronavirus that sickened at least two with respiratory and kidney disease, killing one in the Middle East. The SARS outbreak in 2002 and 2003 caused 50 percent mortality in older adults. A rapid and effective international response ended the outbreak in just four months. The final tally: 8,422 cases of SARS, resulting in 916 deaths.

This colorized scanning electron micrograph reveals the rosette-like appearance of the matured SARS-CoV (coronavirus) particles (arrows). Photo: CDC/Dr. Mary Ng Mah Lee.

The study is the culmination of more than a decade of collaboration between the laboratories of Mark Denison, MD, Craig-Weaver Professor of Pediatrics and professor of pathology, and microbiology and immunology at Vanderbilt University School of Medicine, and Ralph Baric, PhD, professor of epidemiology at the Gillings School of Global Public Health at UNC and of microbiology and immunology in the UNC School of Medicine. The researchers’ aim is to better understand how coronaviruses, which also cause the common cold, evolve and spread between species.

Denison’s lab developed the attenuated SARS virus by disabling a unique exoribonuclease (or ExoN) protein, referred to as a proofreading protein. Previous Vanderbilt studies had shown that disabling ExoN knocks out the virus’s ability to correct mistakes, increases mutations twentyfold, and stops its ability to cause disease, at least in the laboratory setting. Graham, formerly a graduate student in Denison’s lab, was able to continue the work in animal models as a postdoctoral scientist in Baric’s lab.

Coronaviruses are RNA viruses known to have the largest genomes in the RNA viral world. It is now understood that the ExoN proofreading protein allows coronaviruses to maintain their expanded genomes, with many proteins evolved to help them survive and spread. But deactivation of ExoN creates a particularly enticing potential approach to vaccine design.

“Live vaccines in general confer broader and longer-lasting immunity, but the risk of live vaccines is they could potentially revert back to virulence as happened with the live polio vaccine in immunocompromised people,” Baric said. “Our evidence is exciting because a more permanently attenuated virus might be safer. We believe that related approaches can be applied to other important human and animal viruses, resulting in safer vaccines.”

To test the likelihood of reversion to virulence, researchers allow a virus to grow in a host that lacks immunity. In the current study, even in very young, very old and immunocompromised animals, the virus did not kill and could persist for a long time without showing signs of a return to virulence.

“In contrast to science fiction, where mutations are evil and endanger the world, our studies demonstrate that viruses have evolved to tightly control their mutation rates, and changing that rate is detrimental to virus survival and disease in nature,” Denison said. “Since all coronaviruses have the ExoN protein, this method for attenuation could be broadly applicable in coronaviruses.”

“If we can’t have a vaccine ready to administer that works for all coronaviruses, then we at least have a strategy for fast production of a functional vaccine for any new epidemic coronavirus that might arise,” Graham said. “That’s a key take-away point of our paper and what makes it so important in the face of current events,” Graham said.


UNC Gillings School of Global Public Health contact: David Pesci, director of communications, 919-962-2600 or dpesci@unc.edu.

One Response to UNC, Vanderbilt discover new live vaccine approach for SARS and novel coronaviruses

  1. Pingback: Friday ID Conference: “Mechanisms Governing Virus-Induced Disease Severity in the Lung | Institute for Global Health & Infectious Diseases

Leave a Reply

Your email address will not be published. Required fields are marked *